Celltrion rose.
On the 28th, Celltrion finished trading at 216,000 won, up 5.88% (12,000 won).
The government has signed an additional supply contract with Celltrion Pharmaceuticals to supply Celltrion’s COVID-19 antibody treatment ‘Rekkorina’.
Celltrion Pharmaceutical announced on the 27th that it had signed an additional supply contract with the Korea Centers for Disease Control and Prevention (KCDC).
According to Celltrion Pharmaceuticals, about 50,000 units of Rekkona produced by Celltrion will be supplied to designated treatment institutions nationwide during the first quarter of next year.
